诺维本联合顺铂二线治疗晚期乳腺癌

目的 探讨诺维本(长春瑞滨)联合顺铂方案治疗蒽环类和(或)紫杉类耐药晚期乳腺癌的疗效与安全性.方法 73例蒽环类和(或)紫杉类耐药晚期乳腺癌患者接受诺维本联合顺铂方案化疗.诺维本(法国Pierre Fabre公司产品)25 mg/m2,第1天和第8天,静脉滴注;顺铂75～80 mg/m2,静脉滴注, 分割为2～5 d.3周为1个周期,每2个周期治疗结束2周后评价疗效.结果 71例均可评价近期疗效和不良反应,总有效率为63.4%(45/71),完全缓解4.2%(3/71),部分缓解59.2%(42/71),稳定32.4%(23/71),进展4.2%(3/71).既往放疗者疗效优于未放疗者(P=0.029),转移部位为单个者疗效优于多个者(P=0.005).主要不良反应为骨髓抑制和胃肠道反应.结论 诺维本联合顺铂方案是治疗蒽环类和(或)紫杉类耐药晚期乳腺癌安全有效的方案.Abstract：Objective To investigate the efficacy and security of vinorelbine combined with cisplatin in the treatment of advanced breast cancer patients resistant to antracyclines and/or taxanes.Methods Seventy-three patients with advanced breast cancer resistant to anthracyclines and/or taxanes received NP regimen:Vinorelbine(NVB 25 mg/m2,intravenous infusion, day 1,8) plus cisplatin(DDP 75-85 mg/m2,intravenous infusion in 2-5 days).Three weeks as one period of treatment.The evaluation was performed two weeks after every two periods of treatment. Results Seventy-one patients were evaluated for efficacy and toxicity of the therapy, the overall response was 63.4%(45/71),3 cases (4.2%) had complete response,42 cases(59.2%)had partial response,while 23 cases(32.4%) had stable disease and progressive disease were 3 cases(4.2%).The efficacy in patients who had received radiotherapy were more effective than those without radiotherapy(P=0.029).The efficacy in patients with single metastatic organ were more effective than those with multiple organs(P=0.005). The common toxicities were myelosuppression and gastrointestinal reactions.Conclusions Vinorelbine combined with cisplatin are tolerable and effective in the treatment of advanced breast cancer with anthracycine and/or taxanes resistance.

Clinical effects of vinorelbine combined with cisplatin in the treatment of patients with advanced breast cancer

Advanced breast cancer Vinorelbine Cisplatin Combination chemotherapy